Sagent Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Six dead in 'stampede-like' incident at India temple, ANI says
Sagent Pharmaceuticals (SGNT) Numbers Cut at Piper Jafffray Post Q2
August 5, 2015 9:47 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $32.00 (from $35.00) following Q2 results but maintained an Overweight rating.
Amsellem commented, "This morning, Sagent reported a 2Q15 net loss per share of ($0.01), compared to the Street EPS... More
RBC Capital Upgrades Sagent Pharmaceuticals (SGNT) to Outperform
August 4, 2015 11:17 AM EDTRBC Capital upgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Sector Perform to Outperform.
For an analyst ratings summary and ratings history on Sagent Pharmaceuticals click here. For more ratings news on Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $25.11 yesterday.
... MoreSagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c
August 4, 2015 8:54 AM EDTSagent Pharmaceuticals (NASDAQ: SGNT) reported Q2 EPS of ($0.01), $0.06 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $83.28 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.
... More